Projects per year
Personal profile
Education
- 2000 Ph.D., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1996 M.S., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1994 B.S., School of Pharmacy, Taipei Medical University
Experience
- 2023.08- Dean, Research and Development, Taipei Medical University
- 2021- Director, Research Center of Drug Discivery, Taipei Medical University
- 2017- Director, Biomedical Commercialization Center, Taipei Medical University
- 2018-2023 Dean, College of Pharmacy, Taipei Medical University
- 2015-2022 Director, Research Center of Pharmaceutical Sciences and Biotechnology, College of Pharmacy, Taipei Medical University
- 2013-2017 Associate Dean, College of Pharmacy, Taipei Medical University
- 2012-2016 Director, Core Laboratory of Drug Organic Synthesis, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
- 2012- Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2008-2012 Associate Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2004-2008 Assistant Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2000-2004 Postdoctoral Research, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes
Awards
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
Research Interests
- Discovery and Development of small molecular compounds towards IND
- Structure optimization through rational drug design and intelligent modification
- Medicinal Chemistry
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 37 Finished
-
脂肪酸代謝所調控的神經炎症在構建造成腫瘤復發之神經元-巨噬細胞-膠質瘤迴路中的角色-可穿透血腦障蔽腦障蔽且抑制惡性神經膠母細胞瘤發炎之藥物研發(2/3)
Liou, J.-P. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
有機鈀金屬促進關鍵抗腫瘤片段的縫合以建構雙功能抗癌化學結構(3/3)
Liou, J.-P. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
Toll-Like Receptor 7/8 Agonists 和 EZH2 Inhibitors 對於三陰性乳癌的 dual target inhibitor 開發
Liou, J.-P. (PI)
7/1/23 → 2/29/24
Project: A - Government Institution › b - National Science and Technology Council
-
PBX1 Inhibitor Prodrug Synthesis
Liou, J.-P. (PI)
7/1/23 → 2/29/24
Project: A - Government Institution › b - National Science and Technology Council
-
新穎具血腦障壁穿透能力試劑之開發以作為TMZ抗藥性及復發性膠質母細胞瘤用藥
Liou, J.-P. (PI)
1/1/23 → 12/31/23
Project: B - Project of TMU › h - Higher Education Sprout Project
-
Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)
Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., Jul 2024, In: Cell Death and Disease. 15, 7, 490.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents
Sethy, B., Yu, Z. Y., Narwanti, I., Upadhyay, R., Lai, M. J., Lee, S. B. & Liou, J. P., Dec 2024, In: Bioorganic Chemistry. 153, 107771.Research output: Contribution to journal › Article › peer-review
-
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress
Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P. & Hsu, T. I., Apr 1 2024, In: Cancer Letters. 586, 216666.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
Effect of Sulfotyrosine and Negatively Charged Amino Acid of Leech-Derived Peptides on Binding and Inhibitory Activity Against Thrombin
Chen, T.-Y., Shyur, E., Ma, T.-H., Wijeyewickrema, L., Lin, S.-W., Kao, M.-R., Liang, P.-H., Shie, J.-J., Chuang, E.-Y., Liou, J.-P. & Hsieh, Y. S., Feb 1 2024, In: ChemBioChem. 25, 3, p. e202300744 e202300744.Research output: Contribution to journal › Article › peer-review
Open Access -
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo
Sharma, S., Wang, S. A., Yang, W. B., Lin, H. Y., Lai, M. J., Chen, H. C., Kao, T. Y., Hsu, F. L., Nepali, K., Hsu, T. I. & Liou, J. P., Feb 22 2024, In: Journal of Medicinal Chemistry. 67, 4, p. 2963-2985 23 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus)
Datasets
-
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H.-J. (Contributor), Lin, Y.-J. (Contributor), Chao, M.-W. (Contributor), Sung, T.-Y. (Creator), Wu, Y.-W. (Creator), Chen, Y.-Y. (Creator), Lin, M.-H. (Contributor), Liou, J.-P. (Creator), Pan, S.-L. (Contributor) & Yang, C.-R. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
Dataset
-
Additional file 1: of Suberoylanilide hydroxamic acid represses glioma stem-like cells
Chang, K.-Y. (Creator), Wang, J.-Y. (Creator), Chuang, J.-Y. (Creator), Ko, C.-Y. (Contributor), Hsu, T.-I. (Contributor), Chang, W.-C. (Creator), Yeh, S.-H. (Contributor), Liou, J.-P. (Creator), Liu, J.-J. (Contributor) & Hsu, C.-C. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3596465_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3596465_d1.v1
Dataset
-
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Lai, M.-J. (Creator), Lee, C.-H. (Creator), Chao, Y.-H. (Creator), Mehndiratta, S. (Creator), Chen, M.-C. (Creator), Liou, J.-P. (Creator) & Lee, H.-Y. (Creator), Taylor & Francis, 2020
DOI: 10.6084/m9.figshare.13207104.v1, https://tandf.figshare.com/articles/journal_contribution/Effect_of_3-subsitution_of_quinolinehydroxamic_acids_on_selectivity_of_histone_deacetylase_isoforms/13207104/1
Dataset
-
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
Dataset
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I.-T. (Contributor), Kuo, C.-C. (Contributor), Liou, J.-P. (Creator) & Chang, J.-Y. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
Dataset